Skoči na glavni sadržaj

Sažetak sa skupa

https://doi.org/10.15836/ccar2024.106

Statin-naive patients with acute coronary syndrome in Slavonski Brod

Domagoj Mišković orcid id orcid.org/0000-0003-4600-0498 ; General Hospital “Dr. Josip Benčević” Slavonski Brod, Croatia
Krešimir Gabaldo orcid id orcid.org/0000-0002-0116-5929 ; General Hospital “Dr. Josip Benčević” Slavonski Brod, Croatia
Katica Cvitkušić Lukenda orcid id orcid.org/0000-0001-6188-0708 ; General Hospital “Dr. Josip Benčević” Slavonski Brod, Croatia
Ivica Dunđer orcid id orcid.org/0000-0002-3340-7590 ; General Hospital “Dr. Josip Benčević” Slavonski Brod, Croatia
Marijana Knežević Praveček orcid id orcid.org/0000-0002-8727-7357 ; General Hospital “Dr. Josip Benčević” Slavonski Brod, Croatia
Ivan Bitunjac orcid id orcid.org/0000-0002-4396-6628 ; General Hospital “Dr. Josip Benčević” Slavonski Brod, Croatia
Antonija Raguž orcid id orcid.org/0000-0002-7032-2852 ; General Hospital “Dr. Josip Benčević” Slavonski Brod, Croatia
Božo Vujeva orcid id orcid.org/0000-0003-0490-3832 ; General Hospital “Dr. Josip Benčević” Slavonski Brod, Croatia
Ivan Gudelj orcid id orcid.org/0000-0003-0624-7170 ; University of Rijeka, Department of Biotechnology, Rijeka, Croatia
Irzal Hadžibegović orcid id orcid.org/0000-0002-3768-9134 ; Josip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health Osijek, Osijek, Croatia


Puni tekst: engleski pdf 144 Kb

str. 106-106

preuzimanja: 43

citiraj

Preuzmi JATS datoteku


Sažetak

Ključne riječi

acute coronary syndrome; LDL-cholesterol; atorvastatin

Hrčak ID:

314084

URI

https://hrcak.srce.hr/314084

Datum izdavanja:

8.2.2024.

Posjeta: 80 *



During the research on the influence of plasma protein glycosylation on achieving LDL cholesterol target values (1,2), we analyzed statin-naive patients with the first presentation of acute coronary syndrome. Between September 2022 and September 2023, a total of 61 statin-naive patients with acute coronary syndrome were hospitalized. Patients transferred from local hospitals and patients older than 75 years were excluded from the study. Out of 61 patients, 36 had STEMI (ST-segment elevation myocardial infarction) and 25 NSTEMI (Non-ST elevation myocardial infarction). More than 50% of patients were men (35), and the average age of all patients was 58.34 years. 40% of patients are smokers. 55% of patients had a BMI greater than 25 kg/m2. The average value of the initial high-sensitivity troponin was 2337 pg/ml. All patients underwent percutaneous coronary intervention (PCI), and the average number of implanted stents was 1.02. In the largest percentage (38%), the infarct related artery or culprit lesion was on right coronary artery. In patients with STEMI, 57% received a loading dose of prasugrel and the rest ticagrelor. In patients with NSTEMI, after coronary angiography, 83% of patients received prasugrel, the rest ticagrelor and clopidogrel. All patients were discharged with a recommendation to take atorvastatin at a dose of 80 mg per day. The average value of LDL (low-density lipoprotein) cholesterol during hospitalization was 3.97 mmol/L. At the first control, 2 months after PCI, the average value of LDL cholesterol was 2.26 mmol/L, and 4 patients (6%) achieved target values of 1.4 mmol/L. Ezetimibe was recommended to all patients who did not reach the target values. At the second control, 3 months after PCI, the average value of LDL cholesterol was 1.95 mmol/L, and the target values were achieved by 6 patients (9.8%). The plan is to recruit statin-naive patients with acute coronary syndrome until September 2024, and clinical and laboratory follow-up for 1 year after PCI.

LITERATURE

1 

Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 October 12;44(38):3720–826. https://doi.org/10.1093/eurheartj/ehad191 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/37622654

2 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 January 1;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/31504418


This display is generated from NISO JATS XML with jats-html.xsl. The XSLT engine is libxslt.